Savara (SVRA) Tops Q3 EPS by 10c

Savara (NASDAQ: SVRA) reported Q3 EPS of ($0.30), $0.10 better than the analyst estimate of ($0.40).

“Based on the totality of evidence, we continue to believe that Molgradex has a clinically meaningful treatment effect on aPAP and we are committed to this program,” said Rob Neville, Chief Executive Officer, Savara. “In the near-term, gaining clarity on the best regulatory path forward is our highest corporate priority and we look forward to further collaborating with the FDA and EMA in this regard.”

For earnings history and earnings-related data on Savara (SVRA) click here.

You May Also Be Interested In

• Horizon Bancorp faces $3M jury verdict in auto repossession case
• Oppenheimer turns cautious on major U.S. banks, favors alternative asset managers
• AEVEX names Murali Krishnan as chief growth officer